Perrigo/$PRGO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Perrigo

Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.

Ticker

$PRGO
Sector

Primary listing

NYSE

Employees

8,379

Headquarters

Dublin, Ireland

Perrigo Metrics

BasicAdvanced
$3B
-
-$0.58
0.48
$1.15
5.26%

What the Analysts think about Perrigo

Analyst ratings (Buy, Hold, Sell) for Perrigo stock.

Bulls say / Bears say

Perrigo’s FDA approval and launch of a store-brand equivalent to Flonase expands its OTC portfolio and provides access to the allergy treatment market, potentially driving revenue growth. (Reuters)
The company’s tentative FDA approval for a generic version of Soolantra cream positions Perrigo to enter the high-value rosacea treatment segment, enhancing its generics pipeline. (Reuters)
Two FDA actions in the past six months (Flonase equivalent and Soolantra generic) underscore Perrigo’s robust generics pipeline and bode well for sustained product-driven sales momentum. (Reuters, Reuters)
The Flonase store-brand equivalent faces entrenched competition in the crowded OTC allergy market, which could pressure pricing and margins. (Reuters)
The generic Soolantra cream will compete against established dermatology players, heightening the risk of price erosion and limited market share. (Reuters)
Divesting its U.K. generic prescription pharmaceuticals business narrows Perrigo’s portfolio focus, increasing its exposure to consumer self-care cyclicality and reducing revenue diversification. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Perrigo Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Perrigo Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRGO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs